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Introduction
Metachromatic leukodystrophy (MLD) is a storage disorder that is
due to inherited deficiency of the lysosomal enzyme arylsulfatase A
(ARSA; EC 3.1.6.8). The disease is characterized by myelin degener-
ation in both CNS and peripheral nervous system (PNS), associat-
ed with the accumulation of undegraded galactosyl-3-sulfate
ceramide (sulfatide) in glial cells and neurons. The prognosis is
severe, with death resulting, in the majority of cases, a few years after
the diagnosis (1, 2). No effective treatment is currently available. Pro-
tein therapy represents a powerful approach to replace a missing or
nonfunctional enzyme, or to provide trophic and regulatory signals
to affected tissues in a variety of metabolic, degenerative, or inflam-
matory conditions. However, protein delivery poses serious chal-
lenges when sustained administration is required and when the
CNS and PNS are the major disease targets, as in MLD. In fact, the
blood-brain and the blood-nerve barriers may severely limit access
of systemically administered therapeutic molecules to these tissues.
Gene-based delivery may allow the establishment of a sustained
source of therapeutic proteins within the nervous system (NS), over-
coming the anatomical barriers that limit their diffusion from the
circulation (3, 4). Others and we previously showed that direct injec-
tion of gene transfer vectors, or ex vivo–engineered cells, into the
CNS achieved long-term protein expression and therapeutic bene-
fit in several disease models, including MLD (5–9). However, the
probable requirement for multiple injections and the invasiveness
of the procedure may limit its application to humans. Moreover, the
need to target the widespread PNS network poses an additional
challenge. Thus, alternative strategies ensuring widespread delivery
and expression of exogenous genes throughout the NS are required.
Following bone marrow transplantation (BMT), donor-derived
cells have been detected within the CNS (10). The nature and fates
of these CNS-migrated, bone marrow–derived (BM-derived) cells
and their potential trans-differentiation into nonhematopoietic
cells (i.e., neurons or astrocytes) has recently been the subject of
extensive investigations (11–14). Several works supported the
notion that donor BM-derived cells replaced a fraction of the CNS
macrophage/microglia population in a probable process of phys-
iological turnover and that this phenomenon was enhanced upon
tissue damage (15, 16). By genetically marking the transplanted
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BM cells, marker expression was detected in the CNS macrophage/
microglia population, indicating that it is possible to deliver exoge-
nous proteins to the CNS by genetically modified hematopoietic
stem cells (HSCs) (17). The therapeutic potential of this approach
is underscored by the clinical benefit of allogeneic BMT in some
metabolic storage disorders (18, 19). Although the mechanism
underlying the partial efficacy of BMT in controlling CNS disease
is not fully understood, it is considered to reflect, at least in part,
the secretion of functional enzyme by donor-derived cells that have
migrated to the CNS and the subsequent enzyme uptake by the res-
ident enzyme-deficient cells (20, 21). However, several aspects of
the migration of BM-derived cells to the CNS remain to be better
investigated, including their actual cellular source in the BM, their
differentiation potential, kinetics, and extent of migration to dif-
ferent CNS regions in both physiological and pathological condi-
tions. Furthermore, investigation is needed into whether a similar
migration of BM-derived cells takes place in the PNS also and to
what extent genetically modified HSCs can target the widespread
PNS network. Most importantly, the potential therapeutic benefit
of this strategy for disorders characterized by extensive CNS and
PNS involvement such as MLD still requires demonstration. A
major hurdle to overcome before exploiting HSC migration to
reach sustained and effective levels of therapeutic proteins within
the NS is to accomplish efficient gene transfer into the trans-
planted HSCs and stable, robust expression in their progeny. These
are challenging tasks for the vectors currently in clinical studies (3).
Here we set out to address the aforementioned issues taking advan-
tage of lentiviral vectors (LVs) to accomplish efficient HSC transduc-
tion in conditions that allow maintenance of stem cell properties and
that may provide advantages for clinical application, as compared with
currently used protocols (22–24). We transduced purified hematopoi-
etic progenitors by a short ex vivo treatment in the absence of growth
factors and monitored the fate of their gene-marked progeny into the
NS upon transplantation and their potential to correct disease mani-
festations in As2–/– MLD mice, which carry germline inactivation of
the ARSA gene (25). We confirmed and extended previous findings of
progressive repopulation of CNS macrophage/microglia cells by trans-
gene-expressing cells (17), proving the origin of CNS-migrated cells
from long-term repopulating HSCs and their virtually exclusive dif-
ferentiation into mature resting microglia. Moreover, we observed a
faster and more pronounced migration of transgene-expressing
macrophages into several PNS sites, providing direct evidence of PNS
targeting by ex vivo modified cells. All of these findings were enhanced
in MLD mice. Remarkably, when we transduced HSCs from MLD
mice with ARSA-expressing LV and transplanted them into disease-
affected littermates, we obtained full reconstitution of enzyme activi-
ty in the hematopoietic system and almost complete protection from
the motor conduction impairments, motor learning and coordination
deficits, sulfatide storage, and demyelination. These results indicate
that transplantation of LV-transduced autologous HSCs may repre-
sent a long-sought therapeutic option for MLD patients, and possibly
for other neurodegenerative disorders.
Methods
LV production and titration. Vesicular stomatitis virus–pseudotyped
(VSV-pseudotyped) LV stocks were produced by transient cotrans-
fection of the transfer constructs pRRLsin.cPPT.hPGK.eGFP.Wpre
(26) or pRRLsin.cPPT.hPGK.ARSA.Wpre, the late-generation pack-
aging construct pCMV∆R8.74, and the pMD2.G envelope con-
struct in 293T cells, followed by ultracentrifugation of conditioned
medium, as described (27). Stocks were titered by Southern blot
analysis, endpoint expression titer in HeLa cells, and p24 immuno-
capture assay, as described (28).
Mice studies. C57BL/6 and congenic C57BL/6 Ly45.1 mice were pur-
chased from Charles River Laboratories Inc. (Calco, Italy) and main-
tained in germ-free conditions. As2–/– MLD mice were bred in the
H.S. Raffaele animal research facility by intercrossing the homozy-
gous offspring of two carrier mice obtained by rederivation (embryo
transfer) of As2–/– males (25) with C57BL/6 females. Thus, the MLD
mice used in this study have a mixed C57BL6/129 genetic back-
ground. WT C57BL6/129 hybrid mice were purchased from The
Jackson Laboratory (Bar Harbor, Maine, USA) and used as the most
appropriate controls for functional studies. All procedures were per-
formed according to protocols approved by the Animal Care and Use
Committee of the Fondazione San Raffaele del Monte Tabor
(IACUC 163) and communicated to the Ministry of Health and local
authorities according to Italian law.
Transduction of hematopoietic progenitors and BMT. Six-week-old male
immunocompetent C57BL/6 Ly45.1 and As2–/– mice were killed with
CO2, and the BM was harvested by flushing the femurs and the tib-
ias. Hematopoietic progenitors were purified using the Enrichment
of Murine Hematopoietic Progenitors kit (Stem Cell Technologies
Inc., Vancouver, British Columbia, Canada). For transduction, 1 × 106
cells/ml were exposed to increasing doses of the phosphoglycerate
kinase–GFP (PGK-GFP) LV (from 1 × 107 to 1 × 108 HeLa transduc-
ing units/ml [TU/ml]) and PGK-ARSA LV (3 µg viral p24/ml) in
Stem Span SFEM expansion medium (Stem Cell Technologies Inc.),
in the absence of serum and cytokines for 12 hours. Vector- or mock-
transduced cells (106 cells/mouse) were injected via the tail vein into
6-week-old lethally irradiated (a total of 8 Gy divided into two admin-
istrations) C57BL/6 (Ly45.2) or As2–/– female mice. We performed
clonogenic assays by plating 1 × 104 and 5 × 104 hematopoietic pro-
genitors in a methylcellulose-based medium (MethoCult M3434;
Stem Cell Technologies Inc.). Ten days later, colonies were scored for
GFP expression by fluorescence microscopy, plucked, and lysed for
PCR analysis for the detection of LV sequences.
FACScan analysis. Transduced cells were grown for at least 4 days
before FACS analysis to reach steady-state GFP expression and to
rule out pseudo transduction. Before FACS analysis, cells were
washed and resuspended in PBS containing 30 µM propidium
iodide (PI) (Becton Dickinson and Co., Franklin Lakes, New Jersey,
USA) and 2% FBS. For immunostaining, 1 × 105 cells were blocked
in 5% rat serum (Stem Cell Technologies Inc.), 2% FBS in PBS for
15 minutes at 4°C. After blocking, R-phycoerythrin-conjugated
(RPE-conjugated) antibodies (IgG isotype control, anti–Sca-1 and
anti-CD45.1, all from PharMingen, San Diego, California, USA)
were added to a final concentration of 1–5 µg/ml and the cells incu-
bated for 30 minutes at 4°C, then washed, stained with PI, and ana-
lyzed by three-color flow cytometry. Only viable, PI-negative cells
were used for the analysis.
To analyze engraftment, 12 and 24 weeks after transplant blood
and marrow samples were subjected to immunostaining and FACS
analysis following red blood cell lysis with ammonium chloride. Cells
were stained as described above, with RPE-conjugated antibodies
(IgG isotype control, anti–Sca-1, anti-CD45.1, anti-CD4, anti-CD8,
anti-CD11b, and anti-B220, all from PharMingen) and analyzed.
PCR analysis. At sacrifice we performed clonogenic assays by plat-
ing 1 × 104 and 5 × 104 BM cells in a methylcellulose-based medium
(MethoCult M3434; Stem Cell Technologies Inc.). Ten days later,
colonies were scored for GFP expression by fluorescence
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microscopy, plucked, and lysed for PCR analysis for the detection
of LV sequences. Genomic DNA extracted from plucked hematopoi-
etic colonies was subjected to PCR analysis for the HIV-1 leader
region of the LV construct. GAPDH amplification was used to
assess DNA integrity. Primers for the LV amplification were as fol-
lows: forward, 5′-TGAAAGCGAAAGGGAAACCA-3′; reverse, 5′-
CCGTGCGCGCTTCAG-3′. The PCR product length was 64 bp.
Primers for GAPDH amplification were as follows: forward, 5′-
CGCACTTTCTTGTGCAGTG-3′; reverse, 5′-GTTCAGCTCTCTG-
GGATGAC-3′. The PCR product length was 450 bp. The PCR reac-
tion mixture consisted of 20 pmol of each primer, 0.2 mM dNTP, 4
mM MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 1 U Ampli-
Taq Gold DNA polymerase (Applied Biosystems, Foster City, Cali-
fornia, USA). In the case of LV amplification, the first denaturation
step was at 95°C for 10 minutes, followed by 30 cycles of 60 seconds
at 94°C, 60 seconds at 55°C, 60 seconds at 72°C, with the final step
at 72°C for 5 minutes. In the case of GAPDH amplification, the first
denaturation step was at 95°C for 10 minutes, followed by 30 cycles
of 60 seconds at 94°C, 60 seconds at 56°C, 60 seconds at 72°C, with
the final step at 72°C for 5 minutes.
Southern blot analysis. The BM and the spleen of primary and sec-
ondary recipients were harvested for genomic DNA analysis. Twenty
micrograms of genomic DNA and a curve of plasmid standards were
digested with AflII, which cuts twice in the vector sequence, or with
BamHI, which cuts once in the vector sequence. Digested DNA was
separated on a 1% agarose gel, transferred to a nylon membrane
(Hybond-N; Amersham Biosciences, Piscataway, New Jersey, USA) by
capillary transfer, and probed with a radiolabeled woodchuck hep-
atitis virus post-transcriptional regulatory element (Wpre) probe.
Immunofluorescence and fluorescent microscope analysis. Animals were
killed under deep anesthesia and by intracardiac perfusion with 0.9%
NaCl followed by 4% paraformaldehyde (PAF) in PBS, pH 7.4. Organs
were fixed for 10–12 hours in PAF, equilibrated for 48 hours in PBS
containing 15% sucrose, and then embedded in OCT compound for
quick freezing in liquid nitrogen. Six- to ten-micron cryostatic sec-
tions were laid on gelatin-coated slides, washed in PBS, and frozen
at –80°C. For immunofluorescence staining, sections were blocked
with 5% goat serum (Vector Laboratories Inc., Burlingame, Califor-
nia, USA) in PBS containing 1% BSA and 0.1% Triton X-100 (PBS-T).
Primary antibodies were diluted in PBS-T with 2% goat serum, 1%
BSA as follows: IgG2a κ-isotype control clone A110-2, 1:200; F4/80
(MCAP497; Serotec Ltd., Oxford, United Kingdom), clone CI:A3-1,
purified, 1:500; NeuN (MAB377; Chemicon International, Temecu-
la, California, USA), 1:100; glial fibrillary acidic protein (GFAP)
(MCA1909; Serotec Ltd.), clone DP46.109, 1:100; myelin basic pro-
tein (MBP) (MCA408; Serotec Ltd.), 1:100. For GFP staining we used
an affinity-purified rabbit polyclonal antibody (A11122; Molecular
Probes Inc., Eugene, Oregon, USA), 1:100. After incubation for 1
hour at room temperature, sections were washed in PBS-T and
stained for 1 hour with secondary antibodies (goat α-rabbit Alex-
aFluor488 and goat α-rat AlexaFluor546; Molecular Probes Inc.)
diluted 1:500 in PBS-T, 1% BSA. For CD45.1 staining, we used an
RPE-conjugated monoclonal anti-mouse CD45.1 antibody (A20;
PharMingen), 1:50. Slides were mounted with 20% Mowiol in PBS.
Fluorescent and confocal microscopy were performed using a fluo-
rescent microscope Olympus Provis AX70 and a three-laser confocal
microscope (Radiance 2100; Bio-Rad Laboratories Inc., Hercules,
California, USA). Fluorescent signals from single optical sections
were sequentially acquired and analyzed by Adobe Photoshop 5.5
(Adobe Systems Inc., San Jose, California, USA).
Quantification of regional CNS and PNS engraftment. Counts of
GFP+, F4/80+ cells in the CNS and in the PNS were performed on
10-µm cryostatic sections following the immunofluorescence
staining already described. Twenty to thirty brain (cerebrum and
cerebellum) sections and 10–15 PNS (acoustic ganglion, dorsal
root ganglions, and sciatic nerve) sections per mouse were ana-
lyzed from each of three mice per time point. As criteria for cell
counts, only GFP+, F4/80+ cellular bodies, and not cellular pro-
cesses, were counted. Counts were performed twice by two differ-
ent investigators. An unpaired Student’s t test was performed for
statistical evaluation of the data.
ARSA assays. To determine ARSA activity in transduced cells and
in PBMC of ARSA-transplanted mice, cell pellets were lysed in 0.5
M sodium acetate, pH 5, at 4°C for 2 hours. The ARSA activity
was detected using the N-lissamine rhodaminyl-(12-aminodode-
canoyl) cerebroside 3-sulfate (LRh-CS) as substrate (29), adapt-
ing the method for a pyrene containing cerebroside sulfate (30).
The incubation mixtures, in final volumes of 0.25 ml, contained
25 mM sodium acetate buffer (pH 5.0), 5.5 mM sodium tauro-
deoxycholate, 5 mM MnCl2, 50 µg of sample proteins dialyzed
against water, and 125 pmol of LRh-CS. The samples and a blank
were incubated at 37°C for 16 hours, stopped after addition of
0.5 ml of 0.1 M Na2SO4, and adsorbed on a reverse-phase column
(Sep-Pak C18 cartridge; Waters Corp., Milford, Massachusetts,
USA); after exhaustive washing with water, the fluorescent lipids
were recovered by elution with 2 ml of methanol and 2 ml of chlo-
roform/methanol, 6:4. The combined eluates were evaporated
under a nitrogen stream and resolved into bands by TLC on alu-
minum-coated silica gel plates using chloroform/ethylacetate/
n-propanol/0.25% KCl/methanol, 25:25:25:9:16 (by volume). The
spots corresponding to unreacted sulfatide, galactosyl cerebro-
side, ceramide, and free acid were scraped off the plate, extracted
with chloroform/methanol, and their fluorescence measured on
a Jasco FP-770 spectrofluorometer using an excitation wave-
length of 565 nm and an emission of 575 nm. ARSA activity was
also evaluated by p-nitrocatecholsulfate (PNC) assay performed
on 25 µg of sample proteins incubated with 100 µl of 10 mM
PNC for 90 minutes at 37°C. The reaction was stopped with 1 ml
of 1 M NaOH, and the fluorescence was measured in a spec-
trophotometer (515 nm). ARSA activity, expressed in nanomoles
per milligram per hour, was normalized for protein content.
Neurophysiological evaluation. Mice were anesthetized with tri-
choroethanol, 0.02 ml/g of body weight, and placed under a heat-
ing lamp to avoid hypothermia. Using tape, we secured the mice
on a smooth table to prevent movement artifacts due to the elec-
trical stimulation, the lower limbs gently stretched to facilitate the
measurement of distances between proximal and distal points of
stimulation. The sciatic nerve motor conduction velocity (MCV)
was obtained by stimulating the nerve with steel monopolar nee-
dle electrodes. A pair of stimulating electrodes was inserted sub-
cutaneously near the nerve at the ankle; a second pair of electrodes
was placed at the greater ischiatic notch to obtain two distinct
sites of stimulation, distal and proximal, respectively, along the
nerve. The muscular response to the electrical nerve stimulation,
called the compound motor action potential (cMAP), was record-
ed with a pair of recording needle electrodes; the active electrode
was inserted in muscles in the middle of the paw, while the refer-
ence was placed in the skin between the first and second digit.
Motor evoked potentials (MEPs) were recorded with the same
montage described for MCV from the paw muscle with transcra-
research article
The Journal of Clinical Investigation http://www.jci.org Volume 113 Number 8 April 2004 1121
nial electrical stimulation of the motor cortex. The excitatory vol-
leys descending along the corticospinal pathways evoke a motor
potential in the paw muscles through a trans-synaptic depolar-
ization of alpha-motor neurons (cortical MEP, cMEP). The periph-
eral conduction time (PCT) was obtained with a method based on
the F wave latency determination. In fact, the antidromic volley
following nerve stimulation excites the alfa-motor neuron, giving
rise to spikes traveling orthodromically up to the muscle, where
they can be recorded as a late potential called the F wave. The PCT
was thus calculated with the formula (F wavelat + cMAPlat – 1)/2.
The central conduction time (CCT) was measured as the differ-
ence between cMEP and PCT latencies. An unpaired Student’s t
test was performed for statistical evaluation of the data.
Rotarod. A motor learning task was performed with an acceler-
ating rotarod apparatus (Ugo Basile, Comerio, Italy). This rotar-
od equipment is based on a rotating cylinder, 3.2 cm in diameter,
covered with textured rubber. Each section is 6.0 cm wide, allow-
ing five mice to be tested simultaneously, one per section. Mice
walk forward on the rotating cylinder, at speeds increasing from
4 to 40 rpm over a 5-minute test session. Latencies in falling off
the cylinder were measured over 3 days, three trials per session.
Statistical analyses were made by one-way ANOVA using Scheffe’s
test after significant main effect of the treatment was determined.
Histopathology. Mice were killed by CO2 inhalation. The tissues
were removed, fixed in 2% glutaraldehyde, 1% osmium tetroxide,
and embedded in Epon/araldite. Semithin (1-µm-thick) sections
were stained with Toluidine Blue. Six to seven brain (cerebrum and
cerebellum) and sciatic nerve sections per mouse were analyzed
from each of two to four mice per condition. Metachromatic
deposits larger than 20 µm were counted at ×20 magnification,
demyelinated fibers were counted at ×100 magnification. Counts
were performed twice by two different investigators. Microscope
Figure 1
Chimerism and hematologic reconstitution by transgene-expressing cells of transplanted mice. (A) FACS analysis of GFP expression in control (left
panel) and transduced (right panel) purified progenitors. (B) GFP expression in PBMCs of primary and secondary transplanted mice, 3 months
after BMT. Up to 90% of circulating donor CD45.1-, CD11b-, B220-, CD4-, and CD8-positive cells expressed GFP.The means and standard devia-
tions of primary (n =16) and secondary (n = 4) mice are shown. (C) GFP expression by fluorescence microscopy (% GFP+) and transduction level
by PCR (% vector sequence+), in CFCs from progenitors after transduction and from BM of primary and secondary recipients (50–100 CFCs scored
for fluorescence and 20 CFCs analyzed by PCR per each mouse, n = 9).The great majority of CFCs contained LV sequences and expressed GFP
along serial transplants. (D) Southern blot analysis of bone marrow (B) and spleen (S) DNA from transplanted mice.A standard plasmid curve, from
0.5 to 5 vector copies per genome, DNA markers (M) in kb, and control untransplanted mice (Co) are shown.AflII digestion (upper panel) showed
5 or more vector copies integrated per cell in all recipients. BamHI digestion (lower panel) showed a diffuse hybridization pattern in primary mice
indicating oligo- to polyclonal engraftment and the absence of dominant clones. (E) and (F) GFP+ cells in liver (E) and kidney (F) sections of trans-
planted mice, 3 months after BMT, stained as indicated. GFP+ cells expressed F4/80 (3 panels on the right). Scale bar: 20 µm.
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images were taken with a digital camera and processed by Adobe
Photoshop 5.5 software (Adobe Systems Inc.).
Results
Long-term, multilineage, and polyclonal engraftment of LV-transduced
HSCs. We enriched hematopoietic progenitors and stem cells from
total BM of C57BL/6 Ly45.1 mice by lineage markers negative selec-
tion and transduced them using advanced-generation LV express-
ing the GFP marker gene under the control of the PGK promoter.
To ensure full maintenance of stem cell properties, we incubated the
cells for a short time with the vector in the absence of serum and
cytokine stimulation (31). After transduction with optimized vec-
tor amounts (0.5 × 108 to 1 × 108 TU/ml), up to 95% of the cells
expressed the transgene, as assessed by GFP expression in liquid cul-
tures (Figure 1A). To monitor chimerism by allele mismatch, we
injected the transduced cells into lethally irradiated, congenic
C57BL/6 Ly45.2 mice. FACS analysis of blood samples 3–9 months
after the transplant demonstrated stable and high engraftment of
Ly45.1+ donor cells (85–98%, average 92%, of total blood leukocytes;
n = 16), and sustained GFP expression levels (62–95%, average 75%,
of total blood leukocytes; n = 16) in the different hematopoietic cells
lineages of recipient mice (Figure 1B). To verify self-renewal and
long-term repopulating capacity of the transduced HSCs, we used
the BM of primary recipients to perform secondary transplants. We
found multilineage engraftment of transgene-expressing cells and
GFP expression in 69% (53–85%, n = 5) of the total blood leukocytes
(Figure 1B) in the secondary-transplant mice 3 months after the
transplant. PCR analysis and fluorescence microscopy of BM-
derived CFCs of primary and secondary recipients showed that the
vast majority of the CFCs were positive for the vector sequences and
expressed GFP (Figure 1C). Taken together, these results indicated
that we efficiently transduced primitive long-term repopulating
HSCs and that transgene expression was stable for up to 12 months
in their differentiated progeny along serial transplants.
We then investigated the clonal composition and vector integra-
tion levels in the hematopoietic grafts of transplanted mice. South-
Figure 2
Identification of bone marrow–derived vector-expressing cells in the CNS
of transplanted mice. Immunofluorescence analysis of cryostatic sections
from the brains of transplanted mice. Fluorescent signals from single opti-
cal sections were sequentially acquired and are shown individually and
after merging (merge). Immunostaining for GFP (green), F4/80, NeuN,
GFAP, or CD45.1 (red) are indicated. (A) Representative sections from
the cerebellums of transplanted mice, analyzed at 3 months (left panel,
scale bar: 200 µm) and 6 months (middle and right panels, scale bar: 300
µm) after BMT.Three months after BMT, few ramified cells were identified
in the upper cortical layers near the meninges. By 6 months after BMT,
several GFP+ cells were present in the cortex, and small clusters of ram-
ified GFP+ cells were detected throughout the parenchyma. (B–E) Rep-
resentative brain sections from transplanted mice 9 months after BMT,
immunostained as indicated. (B) GFP+ cells showed a ramified, microglial
morphology and F4/80 immunoreactivity. Scale bar: 100 µm. (C and D)
Overlay of GFP staining with the neuronal-specific marker NeuN (C) and
the astrocytic marker GFAP (D) demonstrated separate localization of the
two signals, with GFP+ ramified cells found between neurons and astro-
cytes. Scale bar: 300 µm. (E) CD45.1 immunostaining identified GFP+
cells as donor-derived. Scale bar: 70 µm.
Table 1
Frequency of GFP+, F4/80+ macrophage/microglia in CNS and PNS of WT and As2–/– mice
C57BL/6 mice As2–/– mice
CNS PNS CNS PNS
Ce Cb Ce Cb
3 months, n = 3 7.2 ± 5.8 11.5 ± 6.1A – – – –
6 months, n = 3 12.3 ± 2B 13.4 ± 3.2 57 ± 4.2 21.5 ± 1.65C 27.8 ± 14.7C 90 ± 6.7C
9 months, n = 3 23.9 ± 6D 26.1 ± 8.2D 69.7 ± 13D – – –
Abbreviations: Ce, cerebrum; Cb, cerebellum; n, number of mice examined at each time point. From 20 to 30 CNS and 10 to 15 PNS sections per
mouse were analyzed and pooled. AP < 0.05 compared with Ce. BP < 0.05 compared with 3 months. CP < 0.01 compared with C56BL/6 at 6 months.
DP < 0.01 compared with 6 months.
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ern blot analysis on BM and spleen DNA, digested with AflII to
measure the total vector integration, indicated that an average of
five or more vector copies were integrated per cell in both primary
and secondary recipients (Figure 1D). When the DNA was digested
with BamHI to detect the individual vector integrations, we
observed a diffuse hybridization pattern in most primary-transplant
mice, indicating oligoclonal to polyclonal repopulation by HSCs
carrying multiple vector integrations (Figure 1D). In secondary-
transplant mice, individual bands, which were barely detectable in
a fraction of the primary-transplant mice, became more evident on
a background of diffuse hybridization signal, indicating the pres-
ence of dominant clones and thus engraftment by a fraction of the
primary repopulating HSCs (Figure 1D). These data indicated that,
in our experimental conditions, HSCs were effectively preserved, as
shown by the polyclonal repopulation of transplanted mice, and
efficiently transduced, as shown by the high frequency of gene
marking and by the multiple vector integrations into their progeny.
To better characterize our transplanted mice, we evaluated the
migration of donor transduced HSC progeny into the visceral
organs. We analyzed tissue sections of the liver, kidney, spleen, and
lung 3 months after BMT, when the hematopoietic graft was fully
established. We detected abundant GFP+ cells in the liver with the
morphology of Kupffer cells (Figure 1E), in the kidney with a
branched morphology typical of macrophages (Figure 1F), in the
red and white pulp of the spleen, and in the lung, at the level of
alveoli (not shown). Colocalization studies demonstrated that the
migrated GFP+ cells nearly always coexpressed the macrophage
markers F4/80 and/or CD11b, indicating that they turned over
with the resident, tissue-specific monocyte/macrophage lineage
population. These results showed a substantial contribution of
transduced, donor-derived, hematopoietic lineage cells to the vis-
ceral organs of the recipient mice and stable vector expression in
the extravascular progeny of the transplanted HSCs.
CNS migration of donor transduced HSC progeny and microglia differenti-
ation. To evaluate the timing and the extent of migration of trans-
Figure 3
Identification of bone marrow–derived vector-expressing cells in the
PNS of transplanted mice. Representative cryostatic sections of the
dorsal root ganglion (A), sciatic nerve (B), and acoustic ganglion (C) of
a transplanted mouse, 6 months after BMT, immunostained for GFP,
F4/80, and NeuN, as indicated. (A) Left panel, GFP+ cells were found
in the dorsal root ganglion, surrounding sensory neurons and showing
a macrophage morphology. Scale bar: 60 µm. Right panel, all of the
GFP+ cells coexpressed the macrophage marker F4/80. Scale bar: 200
µm. (B) GFP+ cells were detected in the endoneurial space of the sci-
atic nerve and expressed F4/80. Scale bar: 100 µm. (C) GFP+ cells
were distributed between sensory neurons in the acoustic ganglion and
did not express the neuronal marker NeuN. Scale bar: 200 µm. (D) Vec-
tor-expressing cells in the PNS of a representative secondary transplant
recipient. Cryostatic section from the dorsal root ganglion 4 months after
BMT, immunostained for GFP and F4/80. Scale bar: 150 µm.
Figure 4
Enhanced migration and activated morphology of
vector-expressing cells in the CNS of As2–/– MLD
mice. (A) Cryostatic sections of the corpus callo-
sum of a representative transplanted MLD mouse
6 months after BMT, showing widespread GFP+
cells with a swollen ameboid morphology and
coexpressing F4/80. Scale bar: 80 µm. (B) Cryo-
static sections from the hippocampus of the same
mouse were first immunostained as in A, exam-
ined under the fluorescent microscope (three pan-
els on the left) and then stained with PAS (panel
on the far right).The GFP+, F4/80+ microglia cells
were PAS-reactive, indicating their content of lipid
storage granules. Scale bar: 40 µm.
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duced, donor-derived cells to the host CNS, we analyzed sections from
different brain regions of transplanted mice at 3, 6, and 9 months
after BMT by fluorescence and confocal microscopy for expression of
GFP and cell-specific markers (Figure 2). At 3 months after the trans-
plant, several GFP-expressing cells were detected in the cerebrum and
in the cerebellum. GFP+ cells with a ramified morphology, character-
istic of microglia, were mainly detected in the outer cortical layers near
the meninges (Figure 2A), while less differentiated cells were detect-
ed throughout the brain in association with blood vessels. All of these
CNS-migrated cells strongly expressed GFP, as determined by direct
fluorescence (not shown) and by immunofluorescence staining using
anti-GFP antibody. Immunostaining and confocal analysis revealed
that almost all GFP+ cells expressed the monocyte/macrophage-spe-
cific F4/80 marker (shown as example in Figure 2B). Interestingly, a
higher frequency of ramified cells was found in the cerebellar
parenchyma at the earlier time of analysis after BMT. By 6 and 9
months after BMT, we observed a significant increase (P < 0.01 for
both time points) in the frequency of ramified GFP+ cells, both in the
cerebrum and cerebellum (Figure 2, A and B, and Table 1). At the final
time of analysis, up to 30% of the resident F4/80+ microglia were GFP+
in the cerebrum and in the cerebellum. At this long-term analysis, the
GFP+, F4/80+ cells were often found in clusters in the different regions
of the CNS analyzed, including the neocortex, hippocampus, fimbria,
cerebellar cortex, vermis, and spinal cord. The vast majority of these
cells showed a ramified morphology, identifying them as mature, rest-
ing microglia (Figure 2B). Moreover, the GFP+ cells in the CNS were
negative for NeuN and astrocyte-specific (GFAP) markers in all exam-
ined sections (Figure 2C, D). To further confirm the donor and
hematopoietic origin of CNS-migrated cells, we performed double
immunofluorescence for GFP and the CD45.1 antigen, which was
solely expressed by donor-derived cells. We found that nearly all the
GFP+ cells expressed CD45.1 (Figure 2E), and that CD45.1 expression
was higher in less differentiated, perivascular cells and lower in well-
differentiated, parenchymal microglia cells, as previously reported
(30). Moreover, these CD45.1+, GFP+ cells did not express the host
CD45.2 marker (not shown), thus excluding the concept that GFP
expression was due to uptake of GFP-containing debris from circu-
lating or extravasated cells by host macrophages/microglia. In addi-
tion, the lack of CD45.2 expression by GFP+ cells ruled out any sig-
nificant role of cell fusion in the observed microglia reconstitution by
HSC-derived cells. These results confirmed the origin of CNS-migrat-
ed GFP+ cells from donor HSCs and their virtually exclusive differen-
tiation into mature, resting microglia. We then analyzed the CNS of
secondary transplant recipients, and we found GFP+ cells in the cere-
brum, cerebellum, and spinal cord with a frequency similar to that
observed in primary recipients (data not shown). As in primary hosts,
transduced cells showed a ramified morphology and were positive for
F4/80 expression. This further confirmed that CNS-migrated cells
originated from self-renewing, long-term repopulating HSCs.
PNS migration of donor transduced HSC progeny. We then analyzed
sections from the acoustic and dorsal root ganglions and from the
sciatic nerve of transplanted mice by fluorescent and confocal
Figure 5
ARSA activity reconstitution and neurophysiological analysis of transplanted MLD mice. (A) Sulfatide assay on PBMCs from mice transplanted
with ARSA-transduced (ARSA-LV) or GFP-transduced (As2–/–) HSCs, 7 months after BMT, and from WT mice. Sulfatide metabolism in WT and
reconstituted As2–/– mice is shown by LRh-sulfatide reduction and appearance of galactosylceramide (LRh-GalCer) (average and range of pico-
moles normalized for total protein content). (B) PNC assay on PBMCs as in A.ARSA activity is expressed relative to the value obtained from WT
mice. Full ARSA activity reconstitution and overexpression above the WT level was observed in ARSA-transplanted mice. (C–E) Neurophysio-
logical assessment of central and peripheral motor conduction in 8-month-old MLD mice transplanted with ARSA- or GFP-transduced HSCs, and
WT mice with the same genetic background (n = 15 mice per group). Significantly lower CCTs (C) and F wave latency values (D), and significantly
higher sciatic MCV values (E) were recorded in ARSA- transplanted mice compared with GFP controls. Comparison with WT shows nearly com-
plete prevention of motor conduction impairments (P > 0.05 for all parameters). (F–H) Neurophysiological assessment in the same groups of
ARSA- and mock-transplanted mice as in C–E, at 12 months of age, and in age-matched, WT HSC–transplanted mice (n = 10 mice per group).
The analysis shows maintenance of the therapeutic effect in ARSA-transplanted mice and significantly faster motor conduction as compared with
WT HSC–transplanted ones (*P < 0.01 between ARSA-LV and As2–/–; ***P < 0.05 between ARSA-LV and WT HSC–transplanted mice). Data are
expressed as single recordings and means.
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microscopy for the expression of GFP and cell-specific markers (Fig-
ure 3). Starting 3 months after BMT, we found several GFP+ cells in
all the PNS sites examined (Figure 3A). Immunostaining and con-
focal analysis showed that almost all of the GFP+ cells expressed the
monocyte/macrophage-specific F4/80 marker (Figure 3, A and B).
The GFP+ cells were found between the somata of sensory neurons
in the ganglia and within the endoneurium in the sciatic nerve,
expressed F4/80, and were negative for NeuN (Figure 3C) and for
the Schwann cell–specific MBP marker (data not shown), thus being
identified as endoneurial macrophages. Six months after the trans-
plant, GFP+ cells accounted for 55–60% of the F4/80+ cells in senso-
ry ganglions (acoustic and dorsal root ganglions) and sciatic nerve
(Table 1). Nine months after BMT, we observed a further increase
in the frequency of GFP+ cells in the PNS, reaching 77% and 62% of
the total F4/80+ cells in sensory ganglions and sciatic nerve, respec-
tively, and thus approaching the levels observed in circulating
monocytes. These data indicated an extensive migration of trans-
duced HSC progeny to the PNS occurring with a faster kinetics than
that observed in the CNS. As in primary hosts, we found several
GFP+ cells in the sciatic nerve and in the acoustic and dorsal root
ganglions of secondary-transplant recipients, showing distribution
and surface marker expression similar to those observed in prima-
ry-transplant mice (Figure 3D and other data not shown). Since the
transplanted committed progenitors do not self-renew over the long
term in the host and since donor chimerism of the BM stroma is not
expected in mice transplanted with purified hematopoietic pro-
genitors, the observed CNS and PNS migration of transgene-
expressing cells in secondary-transplant recipients proved their ori-
gin from ex vivo–transduced, primitive HSCs.
CNS and PNS migration in MLD mice. We then investigated the migra-
tion of donor transduced HSC progeny to the CNS and PNS of As2–/–
MLD mice. Others and we previously described the accumulation of
nonmetabolized sulfatide in metachromatic granules in the white
matter, and the glial and neuronal degeneration occurring in selected
regions of the NS of these mice (3, 25). We marked purified
hematopoietic progenitors from As2–/– mice with the PGK-GFP LV
and injected them into lethally irradiated As2–/– recipients. As observed
in the C57BL/6 transplants described above, we found GFP expres-
sion in 69–95% (average 82%, n = 9) of all blood lineages 3 months after
transplant (data not shown). We detected an extensive migration of
GFP+, F4/80+ cells in both the CNS and PNS of As2–/– mice analyzed
6 months after BMT. The transduced, donor-derived cells were par-
ticularly abundant in white matter–rich regions that are preferential-
ly affected by lipid storage, such as the corpus callosum and the hip-
pocampal fimbria (Figure 4). Interestingly, virtually all GFP+, F4/80+
cells in these disease target sites showed the swollen, ameboid mor-
phology of activated microglia (Figure 4) (32, 33) and periodic
acid–Schiff (PAS) reactivity due to sulfatide storage in the cytoplasm
(Figure 4B). The contribution of donor HSC-derived, transduced cells
to the local microglial population was significantly higher (P < 0.01)
than that observed in normal C57BL/6 mice at the same time point
after BMT (Table 1). Similarly, we found abundant GFP+ cells in the
PNS and a higher frequency of these cells with respect to that observed
in WT mice (Table 1). These data indicated enhanced recruitment
from the BM and/or faster turnover of resident macrophage/
microglia population in the NS of MLD mice and preferential target-
ing of lipid storage sites by transgene-expressing activated microglia.
Taken together, they suggest that transplantation of LV-transduced
autologous HSCs may represent a promising gene therapy strategy for
MLD, with the potential to correct an early and most likely critical tar-
get of the disease, such as the macrophage/microglia, and deliver the
therapeutic enzyme throughout the CNS and PNS.
Figure 6
Motor learning and coordination in treated and untreated MLD mice.
Twelve-month-old mice transplanted with ARSA-transduced or WT
HSCs and two cohorts of untreated As2–/– mice of 3 and 12 months of
age were tested on an accelerating rotarod apparatus (n = 12–30 per
group). Latencies to fall off the rotarod were recorded over 3 days, 3 con-
secutive trials per day. Means ± SEM of each day are indicated. Post hoc
comparisons were made by one-way ANOVA using Scheffe’s test after
significant main effect of the treatment was determined. Differences from
12-month-old untreated mice were considered significant at P < 0.05 
(*P < 0.01; **P < 0.001).The decline in motor learning and coordination
was completely prevented by ARSA-transduced HSC transplantation,
whereas WT HSC transplantation was not significantly effective in pre-
venting the development of the motor learning impairment.
Figure 7
Long-term protection from lipid storage in transplanted MLD mice. (A
and B) Toluidine Blue–stained semithin sections of the cerebellum (A)
and the hippocampal fimbria (B) of representative 12-month-old MLD
mice transplanted with GFP-LV– and ARSA-LV–transduced As2–/–
HSCs, or with WT HSCs. Abundant large metachromatic deposits are
present in mock-treated and WT HSC–transplanted mice, whereas they
are almost absent in mice transplanted with gene-corrected cells. Scale
bar: 50 µm. For quantitative data and sample size, see Table 2.
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ARSA activity reconstitution in transplanted MLD mice. To assess the
therapeutic potential of gene-corrected HSC transplantation in pre-
venting disease progression in the CNS and PNS, we transduced
ARSA-deficient HSCs from MLD mice with LV expressing the human
ARSA cDNA (3) or the control GFP marker and transplanted them
into disease-affected littermates. Transduction efficiency was evalu-
ated by LV-specific PCR on CFCs obtained from the transduced
HSCs, as previously described. Up to 90% of the CFCs were positive
for the LV sequence (not shown). ARSA activity reconstitution in the
transduced HSC progeny was evaluated after in vitro liquid culture
by substrate metabolism. The cerebroside 3-sulfate assay showed
complete reconstitution of sulfatide metabolism in ARSA-LV–trans-
duced As2–/– HSCs (not shown). PNC assay demonstrated that ARSA
activity in the transduced cells reached values 5- to 10-fold higher
than those measured in cells from WT controls (not shown). Seven
months after BMT, transplanted MLD mice were analyzed for ARSA
activity in PBMCs. By sulfatide assay, we observed reconstitution of
ARSA-dependent sulfatide metabolism, shown by the breakdown of
input sulfatide and the production of its direct metabolite galacto-
sylceramide (Figure 5A). ARSA specific activity was quantified as four-
to eightfold higher than that observed in WT mice (Figure 5B). These
data demonstrated full, sustained reconstitution of the specific
enzyme activity in the hematopoietic system of transplanted mice to
levels significantly higher than those observed in WT mice.
Protection from motor conduction abnormalities in transplanted MLD
mice. At 4, 7, and 11 months after BMT, when transplanted mice
were 5, 8, and 12 months old, respectively, we performed elec-
troneurographic recordings and MEP. We found a statistically sig-
nificant difference (P < 0.01) between mice transplanted with
ARSA-transduced HSCs and GFP-transduced HSCs in MCV (Fig-
ure 5, C and F), F wave latency (Figure 5, D and G) (the latter two
parameters being evaluated on the sciatic nerve), spinal and corti-
cal MEP latencies (not shown), and CCT (Figure 5E and H).
Remarkably, MLD mice transplanted with gene-corrected HSCs
reached the normal range of each tested parameter, as determined
by performing the same measurements in 8-month-old WT mice
with a comparable genetic background (C57BL/6–SV129 hybrids)
(Figure 5, C–E). These data demonstrated long-lasting and almost
complete protection from motor conduction impairments in MLD
mice transplanted with gene-corrected HSC. Similar evaluations
performed 11 months after the transplant on mice transplanted
with As2–/– ARSA-transduced HSCs or WT HSCs demonstrated a
statistically significant advantage of the gene therapy approach, as
shown by better preserved peripheral conduction (P < 0.05 for MCV
and F wave latency) (Figure 5, F and G). Moreover, WT HSC-trans-
planted mice did not reach a significant increase in CCT because
of high variability in the response to treatment (Figure 5H).
Protection from motor learning and coordination impairment in trans-
planted MLD mice. Mice transplanted at 12 months of age with either
ARSA-transduced HSCs or WT HSCs, and two groups of untreated
MLD mice, 3 and 12 months of age, respectively, were subjected to
the rotarod test to assess motor learning and coordination (34) (Fig-
ure 6). Two-way ANOVA revealed a significant effect of ARSA-trans-
duced HSC transplantation (P < 0.05). Post hoc comparison
revealed a significant deterioration of motor learning and coordi-
nation in 12-month-old, as compared with 3-month-old, untreated
MLD mice (P < 0.001), consistent with previous reports document-
ing the late onset of the disease phenotype in the mouse model (5,
25). Remarkably, the motor learning and coordination impairment
was fully prevented by ARSA-transduced HSC transplantation
(ARSA-transduced HSC vs. untreated 12-month-old mice, P < 0.01;
ARSA-transduced HSC vs. untreated 3-month-old mice, P = 0.99).
As in the case of neurophysiological evaluation, transplantation of
WT HSCs, though showing a trend toward improving mouse per-
formance, did not reach a statistically significant effect (WT HSC
vs. untreated 12-month-old mice, P = 0.52).
Protection from neuropathology in transplanted MLD mice. We then
performed histopathological analysis on the CNS and PNS of
transplanted mice at 12 months of age. We observed a marked
reduction of sulfatide-containing metachromatic granules in the
white matter of the brain and cerebellum of ARSA-transplanted
mice (Figure 7 and Table 2), as compared to age-matched untreat-
ed or control vector-treated mice. On the contrary, mice trans-
Table 2
Quantification of metachromatic deposits and demyelination 
in transplanted and untreated As2–/– mice
Transplanted Sciatic nerve Cerebellum Fimbria
HSC Deposits Demyelination Deposits Deposits
As2–/– +++ + +++ ++++
GFP-LV +++ + ++++ ++++
WT 1 + + +++ ++
WT 2 ++ + ++++ +++
ARSA-LV 1 +/– – + +
ARSA-LV 2 +/– – + ++
ARSA-LV 3 – – +/– +/–
ARSA-LV 4 – – +/– +/–
Neuropathological grading: –, 0; +/–, 1–4; +, 5–10; ++, 6–12; +++,
13–20; ++++, >20 metachromatic deposits ≥20 µm per microscope field
or section at ×20 magnification in cerebellum and fimbria, and of
metachromatic deposits in Schwann cells and demyelinated fibers per
nerve section at ×100 magnification in the sciatic nerve; n = 6 sections
per mouse examined for each site.
Figure 8
Long-term protection from lipid storage and demyelination in
transplanted MLD mice.Toluidine Blue–stained sections of the sci-
atic nerve of representative 12-month-old MLD mice transplanted
with GFP-LV– and ARSA-LV–transduced As2–/– HSCs, or with WT
HSCs. Several demyelinated fibers (arrows) and metachromatic
granules in Schwann cells are present in mock-treated and WT
HSC–transplanted mice, whereas they are almost absent in mice
transplanted with gene-corrected cells. Scale bar: 40 µm. For
quantitative data and sample size, see Table 2.
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planted with WT HSCs showed abundant metachromatic deposits
in the disease target areas (Figure 7 and Table 2). Moreover, in
ARSA-transplanted mice, we observed a reduction in the activated,
ameboid microglia, with the vast majority of microglia in lipid stor-
age sites showing a resting and well-differentiated morphology
(not shown). Consistently with the conduction impairments, we
found demyelinated fibers and abundant metachromatic deposits
in the sciatic nerve of untreated and mock-treated MLD mice (Fig-
ure 8 and Table 2). Mice transplanted with ARSA-transduced cells
showed not only a marked reduction in sulfatide deposits in the
sciatic nerve, but also an almost complete protection from demyeli-
nation (Figure 8 and Table 2). Metachromatic deposits and
demyelinated fibers were instead present in the sciatic nerve of
mice transplanted with WT HSC (Figure 8 and Table 2). These data
indicate that ARSA-LV–transduced HSC transplantation provides
an effective protection from the disease-associated tissue damage.
Moreover, they suggest a critical role of enzyme overexpression in
the HSC progeny, given the limited efficacy of WT HSC transplant.
Discussion
In this work, we demonstrate the potential of genetically modified
HSCs to target gene therapy to the NS and correct MLD in the As2–/–
mouse model. We used LV and optimized conditions to achieve effi-
cient gene transfer into HSCs, robust, long-term gene expression in
their progeny, and polyclonal repopulation of transplanted mice, all
of which are potentially critical advantages in prospective clinical
applications. We showed extensive reconstitution of CNS microglia
and PNS macrophages by the transgene-expressing progeny of long-
term repopulating HSCs. By transplanting HSCs transduced with
the ARSA gene, we fully reconstituted enzyme activity in the
hematopoietic system of MLD mice and prevented the development
of the motor conduction impairments, learning and coordination
deficits, and neuropathological abnormalities typical of the disease.
We proved the origin of NS-migrated cells from long-term repopu-
lating HSCs and their virtually exclusive differentiation into microglia
in the CNS, and into macrophages in the PNS. In the brain, the fre-
quency of transgene-expressing cells increased progressively with
time, as was recently reported in mice transplanted with retroviral vec-
tor–transduced whole BM cells (17), suggesting continuous recruit-
ment from circulating precursors and making it unlikely that radia-
tion-induced tissue damage before BMT was solely responsible for
this phenomenon. This hypothesis is further supported by our pre-
liminary results obtained in mice transplanted after busulfan condi-
tioning (35), in which we confirmed an extensive migration of donor
HSC-derived cells into the recipient NS (A. Biffi et al., unpublished
observations). Transgene-expressing cells were mainly perivascular
and poorly differentiated at earlier times after BMT, while at later
times an increasing fraction of them showed the ramified morphol-
ogy and the widespread CNS distribution of mature resting microglia
(33, 36). These results are consistent with physiological turnover of
resting CNS microglia by recruitment of circulating precursors. They
undermine earlier beliefs that the perivascular subset of microglia is
the only one to be periodically replaced by BM-derived elements (37),
rather suggesting that perivascular cells may represent an intermedi-
ate stage in the process of monocyte differentiation to ramified
mature microglia. Interestingly, we observed a faster rate of appear-
ance of transgene-expressing cells in the cerebellum, possibly reflect-
ing regional diversity of the blood-brain barrier between supratento-
rial and subtentorial structures not only in pathological (38) but also
in physiological conditions. It remains to be determined whether the
CNS-recruited cells underwent local proliferation or were often found
in clusters because of regional variation in the recruitment.
Remarkably, we observed an even more pronounced migration of
transgene-expressing macrophages into several different PNS sites,
indicating an unexpected turnover rate of endoneurial macrophages
via BM recruitment. The frequency of transgene-expressing mono-
cyte lineage cells found in these PNS sites approached that observed
in the BM and peripheral blood when analyzed 6 months after BMT,
indicating a faster turnover of endoneurial macrophages than that
of CNS microglia, and possibly reflecting the more permeable blood-
nerve barrier. The function of endoneurial macrophages in physio-
logical conditions is unclear, although they are known to patrol tis-
sues and provide an early response to damage (39, 40). Their
unexpectedly high frequency and turnover, as revealed by our gene-
marking studies, may also indicate a role in the normal disposal of
nerve components (41). Whatever their role is in the PNS, significant
recruitment of BM-derived macrophages provides an avenue for
vehicle gene therapy to this widespread and hardly accessible tissue.
The potential value of the CNS and PNS gene delivery strategy
proposed here was further highlighted by our observation of
faster and enhanced recruitment of BM-derived transgene-
expressing cells in the NS of MLD mice. The rapid response of
hematogenous macrophages to acute local injury and inflam-
mation is well known and was previously reported for the CNS
after focal cerebral ischemia (17, 42) and for the PNS after sciat-
ic nerve crush injury (43). The mechanisms underlying our find-
ings in the chronic, slowly progressive neuropathology of MLD
mice are less clear, and the implications of our observations may
be relevant for understanding the disease pathogenesis and devel-
oping new therapeutic strategies. In fact, the abundant microglia
recruited from the BM to brain areas particularly affected by lipid
storage showed the typical morphology of activated microglia
and was a preferential target of lipid accumulation. The presence
of astrogliosis and microglial activation with few signs of
demyelination has been previously reported in the NS of MLD
mice (25). These data are of particular interest given the recent
reassessment of the pathogenetic role of microglia in storage
CNS disorders (33, 44). Activated microglia have been proposed
to trigger neuronal and glial cell death by cytokine release
induced by their inability to process the stored lipid. Important-
ly, the gene delivery approach described here corrected the
metabolic deficiency, and probably the pathogenetic role, of a pri-
mary disease target, as shown by the significant reduction in the
frequency of activated microglia cells in the CNS of MLD mice
transplanted with ARSA gene–transduced HSCs. It remains to be
ascertained whether the gene-corrected microglia cells have a sur-
vival advantage over their ARSA-deficient counterparts in the
CNS; if they do, this could possibly contribute to a faster and
more effective reconstitution upon BMT. In addition, the gene-
corrected microglia could become a local source of the therapeu-
tic enzyme for other resident NS populations. Cross-correction
of enzyme-deficient cells has been well demonstrated and consti-
tutes the basis for enzyme replacement therapy and allogeneic
BMT in several lysosomal storage disorders (21). Although cross-
correction of ARSA-deficient murine oligodendrocytes was pre-
viously demonstrated in vitro (45), whether and to what extent it
also occurs in vivo in the experimental settings reported here will
require formal demonstration (see below and also ref. 46).
By performing detailed neurophysiological studies of MLD
mice, we found significant impairments of central and peripher-
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al motor conduction (MCV reduction, increased F wave, MEP and
CCT latencies), which provide useful functional parameters to
monitor disease progression and therapeutic efficacy, and were
not evaluated or assessable in previous studies (3, 25, 47, 48).
Behavioral tests demonstrated a clear decline in motor learning
and coordination in aging MLD mice. Moreover, histopatholog-
ical analysis demonstrated, in addition to the previously
described sulfatide storage throughout the CNS and PNS (5, 25),
demyelination in the sciatic nerve. These abnormalities correlate
well with the functional and behavioral impairments and closely
match the human pathology.
LV-mediated HSC transduction and transplantation restored
ARSA activity in vivo to supranormal levels because of multiple
vector integrations. Remarkably, ARSA overexpression in the HSC
progeny led to almost complete prevention of the motor conduc-
tion and behavioral impairments. Histopathological analysis
showed protection from microglia activation, sulfatide accumu-
lation, and demyelination in the NS. These results suggest that
ARSA overexpression not only corrected the metabolic defect in
microglia cells, which have been directly implicated in disease
pathogenesis, but may also have provided a source of active
enzyme for other cell types in the NS.
Previous transplantation studies using retroviral vector–trans-
duced BM cells failed to observe significant benefits in NS pathol-
ogy and functional parameters in MLD mice (47, 48). It is likely
that the successful outcome of our approach was dependent on the
efficient HSC transduction and robust gene expression in their vas-
cular and extravascular progeny reached by the optimized LVs and
conditions used in this study. Direct comparison with MLD mice
transplanted with WT HSCs showed that the HSC-based gene ther-
apy approach was the only one achieving clear-cut efficacy, high-
lighting the crucial role of enzyme overexpression and indicating
the probable occurrence of in vivo cross-correction. The unique
benefit here achieved by genetically corrected versus WT cells pro-
vides a strong rationale for a future clinical translation of HSC-
based gene therapy in MLD. Further support comes from the poor
clinical outcome of allogeneic BMT in MLD patients (18, 19),
although the complexity of the immunological donor–recipient
interplay in allogeneic BMT is likely to account for significant dif-
ferences between inbred mice and patients, and by the advantages
of an autologous versus allogeneic HSC source. Further studies will
address the safety of LV-mediated HSC gene therapy, and its pos-
sible application to other neurodegenerative disorders.
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